Could Ocugen Be a Millionaire Maker Stock?
If you invested $10,000 in Ocugen (NASDAQ: OCGN) shares last year, that principal would be worth well over $275,000 today. That's an astonishing rate of return, but many new investors are hoping that Ocugen stock could fly even higher. Ocugen is in a partnership with India's Bharat Biotech to develop its coronavirus vaccine, COVAXIN. Recently, COVAXIN demonstrated the ability to provide protection against all three Brazil, U.K., and Indian coronavirus variants.
In an interim phase 3 clinical trial, the vaccine demonstrated 100% efficacy against severe cases of COVID-19. The vaccine is already authorized for use in India. Ocugen plans to commercialize its vaccines in the U.S., but is facing extreme headwinds. Will Ocugen succeed and take investors on an awesome ride?
Image source: Getty Images
Source Fool.com
